ARS Pharmaceuticals, Inc. (SPRY)
NGM · Healthcare · Biotechnology
$4.76
-5.93%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$473.4M
Shares Outstanding
99.4M
P/S (TTM)
4.0x
Exchange
NGM
Currency
USD
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 32.5M | 28.1M | 22.7M | 33.7M |
| Gross Profit | 24.3M | 21.9M | 16.4M | 20.8M |
| Operating Income | (53.2M) | (41.5M) | (60.1M) | (61.5M) |
| Net Income | (51.2M) | (41.3M) | (60.6M) | (62.3M) |
| Diluted EPS | $-0.52 | N/A | $-0.61 | $-0.63 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.3M | 30K | 89.1M | 84.3M |
| Gross Profit | 30K | 88.2M | 63.9M | |
| Operating Income | (35.5M) | (67.5M) | (3.1M) | (179.4M) |
| Net Income | (34.7M) | (54.4M) | 8.0M | (171.3M) |
| Diluted EPS | $-0.87 | $-0.57 | $0.08 | N/A |